Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AYAME: Bardoxolone methyl in diabetic kidney disease
NCT03550443Phase 3Terminated
- Sponsor
- Kyowa Kirin
- Start
- May 2018
- Primary completion
- Nov 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bardoxolone methyl in diabetic kidney disease (DKD), sponsored by Kyowa Kirin. Started May 2018; status: terminated.
02
Drugs
bardoxolone methyl
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT03550443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03550443.